Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
19 Dezembro 2023 - 10:00AM
Business Wire
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that management
will present at the J.P. Morgan 42nd Annual Healthcare Conference
on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET).
The presentation will be webcast live; a link for the webcast
can be found on the Edgewise events page and will be accessible for
replay following the presentation. It is recommended that users
connect to the webcast several minutes prior to the start to ensure
a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
first-in-class therapeutics. EDG-5506 is an orally administered
skeletal myosin inhibitor in clinical trials in patients with
Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as
McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel
cardiac sarcomere modulator for the treatment of HCM and other
disorders of cardiac diastolic dysfunction. The entire team at
Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X
(formerly Twitter), Facebook, Instagram and Threads.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231219829381/en/
Investors & Media Michael Carruthers Chief Financial
Officer ir@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024